title: [Hepatic steatosis : Differential diagnostics and current aspects].
abstract: The frequency of non-alcoholic fatty liver disease (NAFLD) has continously increased over the last few decades in parallel with the increasing prevalence of metabolic syndrome. With the increasing frequency of obesity and type 2 diabetes an increase in non-alcoholic steatohepatitis (NASH) is also to be expected. The NASH-associated liver cirrhosis and primary hepatocellular carcinoma (HCC) are indications for liver transplantation (LTX), which is gaining importance in Germany. In contrast, liver cirrhosis as a result of alcoholic steatohepatitis (ASH) is already the leading cause for LTX in Germany. A significant number of patients with ASH cirrhosis develop HCC. Less common causes of hepatic steatosis are secondary and include chemotherapy-associated steatohepatitis (CASH). In this article the causes, diagnostics and novel therapeutic approaches for the various forms of steatosis are discussed.
authors: Klinik für Gastroenterologie und Hepatologie, Hufelandstr. 55, 45122, Essen, Deutschland.
authors: A
authors: A
authors: Canbay
authors: Klinik für Gastroenterologie und Hepatologie, Hufelandstr. 55, 45122, Essen, Deutschland.
authors: G
authors: G
authors: Gerken
authors: Klinik für Gastroenterologie und Hepatologie, Hufelandstr. 55, 45122, Essen, Deutschland. lars.bechmann@uk-essen.de.
authors: L P
authors: LP
authors: Bechmann
mesh_terms: D050110:Bariatric Surgery / Q000379:methods; D015415:Biomarkers / Q000097:blood; D003131:Combined Modality Therapy / Q000379:methods; D003937:Diagnosis, Differential; D003952:Diagnostic Imaging / Q000379:methods*; D004035:Diet Therapy / Q000379:methods; D019317:Evidence-Based Medicine; D005081:Exercise Therapy / Q000379:methods; D005234:Fatty Liver / Q000097:blood / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D000960:Hypolipidemic Agents
keywords: Alcoholic steatohepatitis; Carcinoma, hepatocellular; Liver cirrhosis; Non-alcoholic fatty liver disease; Steatohepatitis